Kaya Ltd

- Currently, Kaya Limited has no concrete plan for new fundraising through debt or equity. - Management is focused on utilizing existing cash flows for expansion and growth. - They acknowledge the thought process of alternative funding for aggressive growth but have no definite strategy in place yet. - Any updates on fundraising strategies will be announced if they arise in the public domain during the financial year. - Expansion plans currently depend on internal cash flows and generating cash flow remains the priority. - Gross debt stands around Rs.150 Crores with interest costs between 8% to 11%. - Management is concentrating on brand refresh, new clinics, and infrastructure investment within available resources.

- Current focus is on brand refresh, new clinics, and investment in infrastructure to support expansion, primarily within India. (Page 14) - Investment in technology upgrade, especially machines impacting key categories like fairness, pigmentation, and laser hair removal. (Page 5) - Expansion into tier two and tier three cities, opening 2-4 clinics per quarter with careful assessment of market feasibility and profitability. (Pages 5, 6, 14) - No concrete guidance on FY2024 capex amount or future large-scale strategic investments; management is currently focusing on generating cash flow and optimizing existing operations. (Pages 4, 14) - Continued investment in product verticals like nutraceuticals including collagen supplements, biotin, and glutathione for future growth. (Page 4) - The strategy is cautious due to cash flow limitations; alternative funding options are being considered but no firm plans disclosed yet. (Page 14)

- Focus on clinic business growth, especially through increased customer footfall and asset utilization. - Expansion in body contouring vertical, adding this category in multiple cities like Gujarat, Hyderabad, Chennai. - Continued growth in core skin care categories. - Investment in product verticals including nutraceuticals (e.g., collagen supplements, glutathione, biotin). - Gradual push into B2C e-commerce and omni-channel sales (online + offline) without heavy upfront cash burn. - Increased average transaction size by ~20% indicating higher spend per customer, despite lower visit frequency. - Brand refresh, technology upgrades, new clinics, and infrastructure investments planned to drive growth. - Cost optimization efforts in labor and rentals to support profitability and growth. - No immediate plans for aggressive external funding; growth primarily via internal cash flow in the near term. Overall, growth is expected through expanded services, product innovation, better productivity, and measured geographic expansion.

- Kaya Limited aims for growth through brand refresh, new clinics, and investment in infrastructure focused on India expansion (Page 14). - Growth will be mainly driven by clinic business expansion and gradual scaling of the B2C e-commerce vertical (Pages 10, 14). - Clinic expansion planned at 2-4 new clinics per quarter, with EBITDA positivity expected within 12 months and payback around 1.5-2 years per clinic (Page 6). - Focus on improving asset utilization and customer inflow in clinics to enhance profitability (Page 9). - Technology investments will improve service times and customer booking automation, boosting revenue and operational efficiency (Pages 8-9). - Profitability levers include higher productivity, marketing automation, expanding product verticals (e.g., nutraceuticals, body contouring), and cost optimization (Page 8). - Financial growth is constrained by internal cash flows; alternative funding considered for more aggressive expansion but not confirmed (Page 14). - FY2024 finance and employee costs expected broadly flat or single-digit increase, indicating controlled expenses (Page 12).

The transcript from the Kaya Limited Q4 FY2023 Results Conference Call does not provide explicit details on the current or expected order book or pending orders. However, some related insights include: - Focus on increasing new customer footfall to improve utilization of existing clinic assets. - Efforts to improve appointment automation and customer booking experience for better capacity utilization. - Expansion into tier two cities with lower cost structures to build profitability. - No specific figures or commentary on order book or backlog were mentioned. - Growth strategy revolves around brand refresh, new clinics, and investment in infrastructure, mainly funded by internal cash flows. - No concrete plans disclosed regarding external funding or aggressive expansion at this moment. Thus, no quantifiable order book or pending orders data was shared in the discussion.